Aficamten Wins UK Authorization and NICE Access
The UK regulator authorized aficamten for eligible adults with symptomatic obstructive hypertrophic cardiomyopathy, while NICE simultaneously recommended NHS use in England and Wales under a commercial arrangement. The paired decision compresses regulatory and reimbursement…
